Global Non-small Cell Lung Cancer Drugs Market Growth (Status and Outlook) 2025-2031
According to this study, the global Non-small Cell Lung Cancer Drugs market size will reach US$ million by 2031.
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Non-small Cell Lung Cancer Drugs Industry Forecast” looks at past sales and reviews total world Non-small Cell Lung Cancer Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Non-small Cell Lung Cancer Drugs sales for 2025 through 2031. With Non-small Cell Lung Cancer Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-small Cell Lung Cancer Drugs industry.
This Insight Report provides a comprehensive analysis of the global Non-small Cell Lung Cancer Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Non-small Cell Lung Cancer Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-small Cell Lung Cancer Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-small Cell Lung Cancer Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-small Cell Lung Cancer Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-small Cell Lung Cancer Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Non-small Cell Lung Cancer Drugs Industry Forecast” looks at past sales and reviews total world Non-small Cell Lung Cancer Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Non-small Cell Lung Cancer Drugs sales for 2025 through 2031. With Non-small Cell Lung Cancer Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-small Cell Lung Cancer Drugs industry.
This Insight Report provides a comprehensive analysis of the global Non-small Cell Lung Cancer Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Non-small Cell Lung Cancer Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-small Cell Lung Cancer Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-small Cell Lung Cancer Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-small Cell Lung Cancer Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-small Cell Lung Cancer Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Biologics
- Small Molecule Targeted Therapy
- Chemotherapy
- Other
- Lung Adenocarcinoma
- Squamous Cell Lung Carcinoma
- Large-cell Lung Carcinoma
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Merck & Co., Inc.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-small Cell Lung Cancer Drugs Market Size (2020-2031)
2.1.2 Non-small Cell Lung Cancer Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Non-small Cell Lung Cancer Drugs by Country/Region (2020, 2024 & 2031)
2.2 Non-small Cell Lung Cancer Drugs Segment by Type
2.2.1 Biologics
2.2.2 Small Molecule Targeted Therapy
2.2.3 Chemotherapy
2.2.4 Other
2.3 Non-small Cell Lung Cancer Drugs Market Size by Type
2.3.1 Non-small Cell Lung Cancer Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
2.4 Non-small Cell Lung Cancer Drugs Segment by Application
2.4.1 Lung Adenocarcinoma
2.4.2 Squamous Cell Lung Carcinoma
2.4.3 Large-cell Lung Carcinoma
2.5 Non-small Cell Lung Cancer Drugs Market Size by Application
2.5.1 Non-small Cell Lung Cancer Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
3 NON-SMALL CELL LUNG CANCER DRUGS MARKET SIZE BY PLAYER
3.1 Non-small Cell Lung Cancer Drugs Market Size Market Share by Player
3.1.1 Global Non-small Cell Lung Cancer Drugs Revenue by Player (2020-2025)
3.1.2 Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Player (2020-2025)
3.2 Global Non-small Cell Lung Cancer Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 NON-SMALL CELL LUNG CANCER DRUGS BY REGION
4.1 Non-small Cell Lung Cancer Drugs Market Size by Region (2020-2025)
4.2 Global Non-small Cell Lung Cancer Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Non-small Cell Lung Cancer Drugs Market Size Growth (2020-2025)
4.4 APAC Non-small Cell Lung Cancer Drugs Market Size Growth (2020-2025)
4.5 Europe Non-small Cell Lung Cancer Drugs Market Size Growth (2020-2025)
4.6 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Non-small Cell Lung Cancer Drugs Market Size by Country (2020-2025)
5.2 Americas Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025)
5.3 Americas Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-small Cell Lung Cancer Drugs Market Size by Region (2020-2025)
6.2 APAC Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025)
6.3 APAC Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Non-small Cell Lung Cancer Drugs Market Size by Country (2020-2025)
7.2 Europe Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025)
7.3 Europe Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-small Cell Lung Cancer Drugs by Region (2020-2025)
8.2 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025)
8.3 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL NON-SMALL CELL LUNG CANCER DRUGS MARKET FORECAST
10.1 Global Non-small Cell Lung Cancer Drugs Forecast by Region (2026-2031)
10.1.1 Global Non-small Cell Lung Cancer Drugs Forecast by Region (2026-2031)
10.1.2 Americas Non-small Cell Lung Cancer Drugs Forecast
10.1.3 APAC Non-small Cell Lung Cancer Drugs Forecast
10.1.4 Europe Non-small Cell Lung Cancer Drugs Forecast
10.1.5 Middle East & Africa Non-small Cell Lung Cancer Drugs Forecast
10.2 Americas Non-small Cell Lung Cancer Drugs Forecast by Country (2026-2031)
10.2.1 United States Market Non-small Cell Lung Cancer Drugs Forecast
10.2.2 Canada Market Non-small Cell Lung Cancer Drugs Forecast
10.2.3 Mexico Market Non-small Cell Lung Cancer Drugs Forecast
10.2.4 Brazil Market Non-small Cell Lung Cancer Drugs Forecast
10.3 APAC Non-small Cell Lung Cancer Drugs Forecast by Region (2026-2031)
10.3.1 China Non-small Cell Lung Cancer Drugs Market Forecast
10.3.2 Japan Market Non-small Cell Lung Cancer Drugs Forecast
10.3.3 Korea Market Non-small Cell Lung Cancer Drugs Forecast
10.3.4 Southeast Asia Market Non-small Cell Lung Cancer Drugs Forecast
10.3.5 India Market Non-small Cell Lung Cancer Drugs Forecast
10.3.6 Australia Market Non-small Cell Lung Cancer Drugs Forecast
10.4 Europe Non-small Cell Lung Cancer Drugs Forecast by Country (2026-2031)
10.4.1 Germany Market Non-small Cell Lung Cancer Drugs Forecast
10.4.2 France Market Non-small Cell Lung Cancer Drugs Forecast
10.4.3 UK Market Non-small Cell Lung Cancer Drugs Forecast
10.4.4 Italy Market Non-small Cell Lung Cancer Drugs Forecast
10.4.5 Russia Market Non-small Cell Lung Cancer Drugs Forecast
10.5 Middle East & Africa Non-small Cell Lung Cancer Drugs Forecast by Region (2026-2031)
10.5.1 Egypt Market Non-small Cell Lung Cancer Drugs Forecast
10.5.2 South Africa Market Non-small Cell Lung Cancer Drugs Forecast
10.5.3 Israel Market Non-small Cell Lung Cancer Drugs Forecast
10.5.4 Turkey Market Non-small Cell Lung Cancer Drugs Forecast
10.6 Global Non-small Cell Lung Cancer Drugs Forecast by Type (2026-2031)
10.7 Global Non-small Cell Lung Cancer Drugs Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Non-small Cell Lung Cancer Drugs Forecast
11 KEY PLAYERS ANALYSIS
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Non-small Cell Lung Cancer Drugs Product Offered
11.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 AstraZeneca Main Business Overview
11.1.5 AstraZeneca Latest Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Information
11.2.2 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product Offered
11.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Bristol-Myers Squibb Company Main Business Overview
11.2.5 Bristol-Myers Squibb Company Latest Developments
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Information
11.3.2 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product Offered
11.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Eli Lilly and Company Main Business Overview
11.3.5 Eli Lilly and Company Latest Developments
11.4 F. Hoffmann-La Roche Ltd
11.4.1 F. Hoffmann-La Roche Ltd Company Information
11.4.2 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product Offered
11.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 F. Hoffmann-La Roche Ltd Main Business Overview
11.4.5 F. Hoffmann-La Roche Ltd Latest Developments
11.5 Merck & Co., Inc.
11.5.1 Merck & Co., Inc. Company Information
11.5.2 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Product Offered
11.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Merck & Co., Inc. Main Business Overview
11.5.5 Merck & Co., Inc. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-small Cell Lung Cancer Drugs Market Size (2020-2031)
2.1.2 Non-small Cell Lung Cancer Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Non-small Cell Lung Cancer Drugs by Country/Region (2020, 2024 & 2031)
2.2 Non-small Cell Lung Cancer Drugs Segment by Type
2.2.1 Biologics
2.2.2 Small Molecule Targeted Therapy
2.2.3 Chemotherapy
2.2.4 Other
2.3 Non-small Cell Lung Cancer Drugs Market Size by Type
2.3.1 Non-small Cell Lung Cancer Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
2.4 Non-small Cell Lung Cancer Drugs Segment by Application
2.4.1 Lung Adenocarcinoma
2.4.2 Squamous Cell Lung Carcinoma
2.4.3 Large-cell Lung Carcinoma
2.5 Non-small Cell Lung Cancer Drugs Market Size by Application
2.5.1 Non-small Cell Lung Cancer Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
3 NON-SMALL CELL LUNG CANCER DRUGS MARKET SIZE BY PLAYER
3.1 Non-small Cell Lung Cancer Drugs Market Size Market Share by Player
3.1.1 Global Non-small Cell Lung Cancer Drugs Revenue by Player (2020-2025)
3.1.2 Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Player (2020-2025)
3.2 Global Non-small Cell Lung Cancer Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 NON-SMALL CELL LUNG CANCER DRUGS BY REGION
4.1 Non-small Cell Lung Cancer Drugs Market Size by Region (2020-2025)
4.2 Global Non-small Cell Lung Cancer Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Non-small Cell Lung Cancer Drugs Market Size Growth (2020-2025)
4.4 APAC Non-small Cell Lung Cancer Drugs Market Size Growth (2020-2025)
4.5 Europe Non-small Cell Lung Cancer Drugs Market Size Growth (2020-2025)
4.6 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size Growth (2020-2025)
5 AMERICAS
5.1 Americas Non-small Cell Lung Cancer Drugs Market Size by Country (2020-2025)
5.2 Americas Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025)
5.3 Americas Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-small Cell Lung Cancer Drugs Market Size by Region (2020-2025)
6.2 APAC Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025)
6.3 APAC Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Non-small Cell Lung Cancer Drugs Market Size by Country (2020-2025)
7.2 Europe Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025)
7.3 Europe Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-small Cell Lung Cancer Drugs by Region (2020-2025)
8.2 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025)
8.3 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL NON-SMALL CELL LUNG CANCER DRUGS MARKET FORECAST
10.1 Global Non-small Cell Lung Cancer Drugs Forecast by Region (2026-2031)
10.1.1 Global Non-small Cell Lung Cancer Drugs Forecast by Region (2026-2031)
10.1.2 Americas Non-small Cell Lung Cancer Drugs Forecast
10.1.3 APAC Non-small Cell Lung Cancer Drugs Forecast
10.1.4 Europe Non-small Cell Lung Cancer Drugs Forecast
10.1.5 Middle East & Africa Non-small Cell Lung Cancer Drugs Forecast
10.2 Americas Non-small Cell Lung Cancer Drugs Forecast by Country (2026-2031)
10.2.1 United States Market Non-small Cell Lung Cancer Drugs Forecast
10.2.2 Canada Market Non-small Cell Lung Cancer Drugs Forecast
10.2.3 Mexico Market Non-small Cell Lung Cancer Drugs Forecast
10.2.4 Brazil Market Non-small Cell Lung Cancer Drugs Forecast
10.3 APAC Non-small Cell Lung Cancer Drugs Forecast by Region (2026-2031)
10.3.1 China Non-small Cell Lung Cancer Drugs Market Forecast
10.3.2 Japan Market Non-small Cell Lung Cancer Drugs Forecast
10.3.3 Korea Market Non-small Cell Lung Cancer Drugs Forecast
10.3.4 Southeast Asia Market Non-small Cell Lung Cancer Drugs Forecast
10.3.5 India Market Non-small Cell Lung Cancer Drugs Forecast
10.3.6 Australia Market Non-small Cell Lung Cancer Drugs Forecast
10.4 Europe Non-small Cell Lung Cancer Drugs Forecast by Country (2026-2031)
10.4.1 Germany Market Non-small Cell Lung Cancer Drugs Forecast
10.4.2 France Market Non-small Cell Lung Cancer Drugs Forecast
10.4.3 UK Market Non-small Cell Lung Cancer Drugs Forecast
10.4.4 Italy Market Non-small Cell Lung Cancer Drugs Forecast
10.4.5 Russia Market Non-small Cell Lung Cancer Drugs Forecast
10.5 Middle East & Africa Non-small Cell Lung Cancer Drugs Forecast by Region (2026-2031)
10.5.1 Egypt Market Non-small Cell Lung Cancer Drugs Forecast
10.5.2 South Africa Market Non-small Cell Lung Cancer Drugs Forecast
10.5.3 Israel Market Non-small Cell Lung Cancer Drugs Forecast
10.5.4 Turkey Market Non-small Cell Lung Cancer Drugs Forecast
10.6 Global Non-small Cell Lung Cancer Drugs Forecast by Type (2026-2031)
10.7 Global Non-small Cell Lung Cancer Drugs Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Non-small Cell Lung Cancer Drugs Forecast
11 KEY PLAYERS ANALYSIS
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Non-small Cell Lung Cancer Drugs Product Offered
11.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 AstraZeneca Main Business Overview
11.1.5 AstraZeneca Latest Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Information
11.2.2 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product Offered
11.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Bristol-Myers Squibb Company Main Business Overview
11.2.5 Bristol-Myers Squibb Company Latest Developments
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Information
11.3.2 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product Offered
11.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Eli Lilly and Company Main Business Overview
11.3.5 Eli Lilly and Company Latest Developments
11.4 F. Hoffmann-La Roche Ltd
11.4.1 F. Hoffmann-La Roche Ltd Company Information
11.4.2 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product Offered
11.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 F. Hoffmann-La Roche Ltd Main Business Overview
11.4.5 F. Hoffmann-La Roche Ltd Latest Developments
11.5 Merck & Co., Inc.
11.5.1 Merck & Co., Inc. Company Information
11.5.2 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Product Offered
11.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Merck & Co., Inc. Main Business Overview
11.5.5 Merck & Co., Inc. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Non-small Cell Lung Cancer Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Non-small Cell Lung Cancer Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Biologics
Table 4. Major Players of Small Molecule Targeted Therapy
Table 5. Major Players of Chemotherapy
Table 6. Major Players of Other
Table 7. Non-small Cell Lung Cancer Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 8. Global Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025) & ($ millions)
Table 9. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
Table 10. Non-small Cell Lung Cancer Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025) & ($ millions)
Table 12. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
Table 13. Global Non-small Cell Lung Cancer Drugs Revenue by Player (2020-2025) & ($ millions)
Table 14. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Player (2020-2025)
Table 15. Non-small Cell Lung Cancer Drugs Key Players Head office and Products Offered
Table 16. Non-small Cell Lung Cancer Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Non-small Cell Lung Cancer Drugs Market Size by Region (2020-2025) & ($ millions)
Table 20. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Region (2020-2025)
Table 21. Global Non-small Cell Lung Cancer Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 22. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Country/Region (2020-2025)
Table 23. Americas Non-small Cell Lung Cancer Drugs Market Size by Country (2020-2025) & ($ millions)
Table 24. Americas Non-small Cell Lung Cancer Drugs Market Size Market Share by Country (2020-2025)
Table 25. Americas Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025) & ($ millions)
Table 26. Americas Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
Table 27. Americas Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025) & ($ millions)
Table 28. Americas Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
Table 29. APAC Non-small Cell Lung Cancer Drugs Market Size by Region (2020-2025) & ($ millions)
Table 30. APAC Non-small Cell Lung Cancer Drugs Market Size Market Share by Region (2020-2025)
Table 31. APAC Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025) & ($ millions)
Table 32. APAC Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025) & ($ millions)
Table 33. Europe Non-small Cell Lung Cancer Drugs Market Size by Country (2020-2025) & ($ millions)
Table 34. Europe Non-small Cell Lung Cancer Drugs Market Size Market Share by Country (2020-2025)
Table 35. Europe Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025) & ($ millions)
Table 36. Europe Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025) & ($ millions)
Table 37. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Region (2020-2025) & ($ millions)
Table 38. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025) & ($ millions)
Table 39. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Non-small Cell Lung Cancer Drugs
Table 41. Key Market Challenges & Risks of Non-small Cell Lung Cancer Drugs
Table 42. Key Industry Trends of Non-small Cell Lung Cancer Drugs
Table 43. Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Region (2026-2031) & ($ millions)
Table 44. Global Non-small Cell Lung Cancer Drugs Market Size Market Share Forecast by Region (2026-2031)
Table 45. Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Type (2026-2031) & ($ millions)
Table 46. Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Application (2026-2031) & ($ millions)
Table 47. AstraZeneca Details, Company Type, Non-small Cell Lung Cancer Drugs Area Served and Its Competitors
Table 48. AstraZeneca Non-small Cell Lung Cancer Drugs Product Offered
Table 49. AstraZeneca Non-small Cell Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 50. AstraZeneca Main Business
Table 51. AstraZeneca Latest Developments
Table 52. Bristol-Myers Squibb Company Details, Company Type, Non-small Cell Lung Cancer Drugs Area Served and Its Competitors
Table 53. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product Offered
Table 54. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 55. Bristol-Myers Squibb Company Main Business
Table 56. Bristol-Myers Squibb Company Latest Developments
Table 57. Eli Lilly and Company Details, Company Type, Non-small Cell Lung Cancer Drugs Area Served and Its Competitors
Table 58. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product Offered
Table 59. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 60. Eli Lilly and Company Main Business
Table 61. Eli Lilly and Company Latest Developments
Table 62. F. Hoffmann-La Roche Ltd Details, Company Type, Non-small Cell Lung Cancer Drugs Area Served and Its Competitors
Table 63. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product Offered
Table 64. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 65. F. Hoffmann-La Roche Ltd Main Business
Table 66. F. Hoffmann-La Roche Ltd Latest Developments
Table 67. Merck & Co., Inc. Details, Company Type, Non-small Cell Lung Cancer Drugs Area Served and Its Competitors
Table 68. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Product Offered
Table 69. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 70. Merck & Co., Inc. Main Business
Table 71. Merck & Co., Inc. Latest Developments
Table 1. Non-small Cell Lung Cancer Drugs Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Non-small Cell Lung Cancer Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Biologics
Table 4. Major Players of Small Molecule Targeted Therapy
Table 5. Major Players of Chemotherapy
Table 6. Major Players of Other
Table 7. Non-small Cell Lung Cancer Drugs Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 8. Global Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025) & ($ millions)
Table 9. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
Table 10. Non-small Cell Lung Cancer Drugs Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 11. Global Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025) & ($ millions)
Table 12. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
Table 13. Global Non-small Cell Lung Cancer Drugs Revenue by Player (2020-2025) & ($ millions)
Table 14. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Player (2020-2025)
Table 15. Non-small Cell Lung Cancer Drugs Key Players Head office and Products Offered
Table 16. Non-small Cell Lung Cancer Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Non-small Cell Lung Cancer Drugs Market Size by Region (2020-2025) & ($ millions)
Table 20. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Region (2020-2025)
Table 21. Global Non-small Cell Lung Cancer Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 22. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Country/Region (2020-2025)
Table 23. Americas Non-small Cell Lung Cancer Drugs Market Size by Country (2020-2025) & ($ millions)
Table 24. Americas Non-small Cell Lung Cancer Drugs Market Size Market Share by Country (2020-2025)
Table 25. Americas Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025) & ($ millions)
Table 26. Americas Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
Table 27. Americas Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025) & ($ millions)
Table 28. Americas Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
Table 29. APAC Non-small Cell Lung Cancer Drugs Market Size by Region (2020-2025) & ($ millions)
Table 30. APAC Non-small Cell Lung Cancer Drugs Market Size Market Share by Region (2020-2025)
Table 31. APAC Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025) & ($ millions)
Table 32. APAC Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025) & ($ millions)
Table 33. Europe Non-small Cell Lung Cancer Drugs Market Size by Country (2020-2025) & ($ millions)
Table 34. Europe Non-small Cell Lung Cancer Drugs Market Size Market Share by Country (2020-2025)
Table 35. Europe Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025) & ($ millions)
Table 36. Europe Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025) & ($ millions)
Table 37. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Region (2020-2025) & ($ millions)
Table 38. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Type (2020-2025) & ($ millions)
Table 39. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Application (2020-2025) & ($ millions)
Table 40. Key Market Drivers & Growth Opportunities of Non-small Cell Lung Cancer Drugs
Table 41. Key Market Challenges & Risks of Non-small Cell Lung Cancer Drugs
Table 42. Key Industry Trends of Non-small Cell Lung Cancer Drugs
Table 43. Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Region (2026-2031) & ($ millions)
Table 44. Global Non-small Cell Lung Cancer Drugs Market Size Market Share Forecast by Region (2026-2031)
Table 45. Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Type (2026-2031) & ($ millions)
Table 46. Global Non-small Cell Lung Cancer Drugs Market Size Forecast by Application (2026-2031) & ($ millions)
Table 47. AstraZeneca Details, Company Type, Non-small Cell Lung Cancer Drugs Area Served and Its Competitors
Table 48. AstraZeneca Non-small Cell Lung Cancer Drugs Product Offered
Table 49. AstraZeneca Non-small Cell Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 50. AstraZeneca Main Business
Table 51. AstraZeneca Latest Developments
Table 52. Bristol-Myers Squibb Company Details, Company Type, Non-small Cell Lung Cancer Drugs Area Served and Its Competitors
Table 53. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Product Offered
Table 54. Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 55. Bristol-Myers Squibb Company Main Business
Table 56. Bristol-Myers Squibb Company Latest Developments
Table 57. Eli Lilly and Company Details, Company Type, Non-small Cell Lung Cancer Drugs Area Served and Its Competitors
Table 58. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Product Offered
Table 59. Eli Lilly and Company Non-small Cell Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 60. Eli Lilly and Company Main Business
Table 61. Eli Lilly and Company Latest Developments
Table 62. F. Hoffmann-La Roche Ltd Details, Company Type, Non-small Cell Lung Cancer Drugs Area Served and Its Competitors
Table 63. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Product Offered
Table 64. F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 65. F. Hoffmann-La Roche Ltd Main Business
Table 66. F. Hoffmann-La Roche Ltd Latest Developments
Table 67. Merck & Co., Inc. Details, Company Type, Non-small Cell Lung Cancer Drugs Area Served and Its Competitors
Table 68. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Product Offered
Table 69. Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 70. Merck & Co., Inc. Main Business
Table 71. Merck & Co., Inc. Latest Developments
LIST OF FIGURES
Figure 1. Non-small Cell Lung Cancer Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Non-small Cell Lung Cancer Drugs Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Non-small Cell Lung Cancer Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Non-small Cell Lung Cancer Drugs Sales Market Share by Country/Region (2024)
Figure 8. Non-small Cell Lung Cancer Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Type in 2024
Figure 10. Non-small Cell Lung Cancer Drugs in Lung Adenocarcinoma
Figure 11. Global Non-small Cell Lung Cancer Drugs Market: Lung Adenocarcinoma (2020-2025) & ($ millions)
Figure 12. Non-small Cell Lung Cancer Drugs in Squamous Cell Lung Carcinoma
Figure 13. Global Non-small Cell Lung Cancer Drugs Market: Squamous Cell Lung Carcinoma (2020-2025) & ($ millions)
Figure 14. Non-small Cell Lung Cancer Drugs in Large-cell Lung Carcinoma
Figure 15. Global Non-small Cell Lung Cancer Drugs Market: Large-cell Lung Carcinoma (2020-2025) & ($ millions)
Figure 16. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Application in 2024
Figure 17. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Player in 2024
Figure 18. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Region (2020-2025)
Figure 19. Americas Non-small Cell Lung Cancer Drugs Market Size 2020-2025 ($ millions)
Figure 20. APAC Non-small Cell Lung Cancer Drugs Market Size 2020-2025 ($ millions)
Figure 21. Europe Non-small Cell Lung Cancer Drugs Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size 2020-2025 ($ millions)
Figure 23. Americas Non-small Cell Lung Cancer Drugs Value Market Share by Country in 2024
Figure 24. United States Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Non-small Cell Lung Cancer Drugs Market Size Market Share by Region in 2024
Figure 29. APAC Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
Figure 30. APAC Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
Figure 31. China Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 35. India Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Non-small Cell Lung Cancer Drugs Market Size Market Share by Country in 2024
Figure 38. Europe Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
Figure 39. Europe Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
Figure 40. Germany Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 41. France Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 54. APAC Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 55. Europe Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 57. United States Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 58. Canada Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 59. Mexico Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 60. Brazil Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 61. China Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 62. Japan Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 63. Korea Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 65. India Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 66. Australia Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 67. Germany Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 68. France Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 69. UK Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 70. Italy Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 71. Russia Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 72. Egypt Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 73. South Africa Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 74. Israel Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 75. Turkey Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 76. Global Non-small Cell Lung Cancer Drugs Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Non-small Cell Lung Cancer Drugs Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 1. Non-small Cell Lung Cancer Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Non-small Cell Lung Cancer Drugs Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Non-small Cell Lung Cancer Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Non-small Cell Lung Cancer Drugs Sales Market Share by Country/Region (2024)
Figure 8. Non-small Cell Lung Cancer Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Type in 2024
Figure 10. Non-small Cell Lung Cancer Drugs in Lung Adenocarcinoma
Figure 11. Global Non-small Cell Lung Cancer Drugs Market: Lung Adenocarcinoma (2020-2025) & ($ millions)
Figure 12. Non-small Cell Lung Cancer Drugs in Squamous Cell Lung Carcinoma
Figure 13. Global Non-small Cell Lung Cancer Drugs Market: Squamous Cell Lung Carcinoma (2020-2025) & ($ millions)
Figure 14. Non-small Cell Lung Cancer Drugs in Large-cell Lung Carcinoma
Figure 15. Global Non-small Cell Lung Cancer Drugs Market: Large-cell Lung Carcinoma (2020-2025) & ($ millions)
Figure 16. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Application in 2024
Figure 17. Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Player in 2024
Figure 18. Global Non-small Cell Lung Cancer Drugs Market Size Market Share by Region (2020-2025)
Figure 19. Americas Non-small Cell Lung Cancer Drugs Market Size 2020-2025 ($ millions)
Figure 20. APAC Non-small Cell Lung Cancer Drugs Market Size 2020-2025 ($ millions)
Figure 21. Europe Non-small Cell Lung Cancer Drugs Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size 2020-2025 ($ millions)
Figure 23. Americas Non-small Cell Lung Cancer Drugs Value Market Share by Country in 2024
Figure 24. United States Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Non-small Cell Lung Cancer Drugs Market Size Market Share by Region in 2024
Figure 29. APAC Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
Figure 30. APAC Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
Figure 31. China Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 35. India Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Non-small Cell Lung Cancer Drugs Market Size Market Share by Country in 2024
Figure 38. Europe Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
Figure 39. Europe Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
Figure 40. Germany Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 41. France Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Non-small Cell Lung Cancer Drugs Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 54. APAC Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 55. Europe Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 57. United States Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 58. Canada Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 59. Mexico Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 60. Brazil Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 61. China Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 62. Japan Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 63. Korea Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 65. India Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 66. Australia Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 67. Germany Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 68. France Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 69. UK Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 70. Italy Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 71. Russia Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 72. Egypt Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 73. South Africa Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 74. Israel Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 75. Turkey Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
Figure 76. Global Non-small Cell Lung Cancer Drugs Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global Non-small Cell Lung Cancer Drugs Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries Non-small Cell Lung Cancer Drugs Market Size 2026-2031 ($ millions)
